The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Lee, Chao Wei ^a,b   Kuo, Wen Ling ^a,b   Yu, Ming Chin ^a,b   Chen, Tse Ching ^a   Tsai, Chi Neu ^b   Lee, Wei Chen ^a,b   Chen, Miin Fu ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

CK19; Hepatocellular carcinoma; Lymph node metastasis

Indexed keywords

CYTOKERATIN 19;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH NODE METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-19; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878815670     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-136     Document Type: Article

References (35)

1. Department of Health Report of leading cancer-related death 2010, Taipei, Taiwan, R.O.C.: Department of Health, Department of Health.
2. Uenishi T, Hirohashi K, Shuto T, Kubo S, Tanaka H, Sakata C, Ikebe T, Kinoshita H. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surg Today 2000, 30:892-895. 10.1007/s005950070040, 11059728.
3. Chu KM, Lai EC, Al-Hadeedi S, Arcilla CE, Lo CM, Liu CL, Fan ST, Wong J. Intrahepatic cholangiocarcinoma. World J Surg 1997, 21:301-305. 10.1007/s002689900233, 9015175.
4. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999, 6:122-127. 10.1007/s005340050094, 10398898.
5. Mitchell JD, Mathinsen DJ, Wright CD. Resection for bronchogenetic carcinoma involving the carina: long-term results and effect of nodal status on outcome. J Thorac Cardiovasc Surg 2001, 121:465-471. 10.1067/mtc.2001.112832, 11241081.
6. Hsu CP, Chen CY, Hsia JY, Shai SE. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardio Thorac Surg 2001, 19:10-13.
7. Miyao N, Masumori N, Takahashi A, Sasai M, Hisataki T, Kitamura H, Satoh M, Tsukamoto T. Lymph node metastasis in patients with carcinomas of the renal pelvis and ureter. Eur Urol 1998, 33:180-185. 10.1159/000019552, 9519361.
8. Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit?. Ann Surg Oncol 2000, 7:253-255. 10.1007/s10434-000-0253-0, 10819363.
9. Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Nimura Y. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001, 233:385-392. 10.1097/00000658-200103000-00013, 1421255, 11224627.
10. Pichlmayr R, Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, Ringe B. Surgical treatment in proximal bile duct cancer A single-center experience. Ann Surg 1996, 224:628-638. 10.1097/00000658-199611000-00007, 1235440, 8916878.
11. Ogura Y, Kawarada Y. Surgical strategies for carcinoma of the hepatic duct confluence. Br J Surg 1998, 85:20-24. 10.1046/j.1365-2168.1998.00532.x, 9462376.
12. Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, Wu TJ, Chen MF. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg 2011, 34:53-62. 10.1016/S1015-9584(11)60020-1, 21723467.
13. Corcelle V, Stieger B, Gjinovci A, Wollheim CB, Gauthier BR. Characterization of two distinct liver progenitor cell subpopulations of hematopoietic and hepatic origins. Exp Cell Res 2006, 312:2826-2836. 10.1016/j.yexcr.2006.05.007, 16781709.
14. Yamamoto T, Uenishi T, Ogawa M, Ichikawa T, Hai S, Sakabe K, Tanaka S, Kato H, Mikami S, Ikebe T, Tanaka H, Ito S, Kaneda K, Hirohashi K, Kubo S. Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg 2005, 22:364-370. 10.1159/000090515, 16374007.
15. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003, 94:851-857. 10.1111/j.1349-7006.2003.tb01366.x, 14556657.
16. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Wu WZ, Tan YS. Nuclear accumulation of CXCR4 and overexpressions of VEGF-C and CK19 are associated with a higher risk of lymph node metastasis in hepatocellular carcinoma. Chung Hua Chung Liu Tsa Chih 2010, 32:344-349.
17. Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu WZ, Tan YS, Hou J, Tang ZY, Qin LX, Sun HC. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008, 112:2740-2748. 10.1002/cncr.23488, 18412155.
18. Sun HC, Qin LX, Wang L, Ye QH, Wu ZQ, Fan J, Tang ZY. Risk factors for postoperative complications after liver resection. Hepatobiliary Pancreat Dis Int 2005, 4:370-374.
19. Desmet VJ. Organizational principles. The liver: biology and pathology 2001, 3-15. Philadelphia: Lippincott Williams & Wilkins, Arias IM, Boyer JL, Chisari FV.
20. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996, 56:3004-3009.
21. Tee LB, Kirilak Y, Huang WH, Smith PG, Morgan RH, Yeoh GC. Dual phenotypic expression of hepatocytes and bile ductular markers in developing and preneoplastic rat liver. Carcinogenesis 1996, 17:251-259.
22. Kurokawa I, Urakawa Y, Senba Y, Kawabata E, Nishimura K, Omoto Y, Tokime K, Mizutani H, Tsubura A. Keratin profiles may differ between intraepidermal and intradermal invasive eccrine porocarcinoma. Oncol Rep 2006, 16:473-477.
23. Yang XJ, Lecksell K, Gaudin P, Ji E. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999, 23:147-152. 10.1097/00000478-199902000-00002, 9989840.
24. Wang GF, Lai MD, Yang RR, Chen PH, Su YY, Lv BJ, Sun LP, Huang Q, Chen SZ. Histological types and significance of bronchial epithelial dysplasia. Mod Pathol 2006, 19:429-437. 10.1038/modpathol.3800553, 16415791.
25. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000, 33:76-84. 10.1016/S0168-8278(00)80162-2, 10905589.
26. Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998, 33:318-324. 10.1046/j.1365-2559.1998.00522.x, 9822920.
27. Van-Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988, 19:562-568. 10.1016/S0046-8177(88)80205-3, 2453442.
28. Fischer HP, Altmannsberger M, Weber K, Osborn M. Keratin polypeptides in malignant epithelial liver tumors differential diagnostic and histogenetic aspects. Am J Pathol 1987, 127:530-537. 1899775, 2438941.
29. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers clinical and biological implications. Am J Pathol 1996, 149:1167-1175. 1865193, 8863666.
30. Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Ogawa M, Tanaka H, Shuto T, Kinoshita H. Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett 2002, 178:107-112. 10.1016/S0304-3835(01)00813-8, 11849748.
31. Roskams T, Vos RD, Von-Eyken PV, Myazaki H, Van-Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 1998, 29:455-463. 10.1016/S0168-8278(98)80065-2, 9764994.
32. Haque S, Haruna Y, Saito K, Nalesnik MA, Atillasoy E, Thung SN, Gerber MA. Identification of bipotential progenitor cells in human liver regeneration. Lab Invest 1996, 75:699-705.
33. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010, 30:35-51. 10.1055/s-0030-1247131, 3668687, 20175032.
34. Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn J Clin Oncol 2010, 40:891-896. 10.1093/jjco/hyq099, 20603246.
35. Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi M, Harada K, Sasaki M, Matsui O, Nakanuma Y. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest 2011, 91:262-272. 10.1038/labinvest.2010.161, 20856226.